Posts tagged David Luci
Dipexium updates availability of Phase 3 data

Dipexium Pharmaceuticals (NASDAQ:DPRX) updated the status of results from two pivotal Phase 3 clinical trials - OneStep-1 and OneStep-2- of its topical antimicrobial peptide, Locilex, for the treatment of diabetic foot ulcers.

Data tables and listings from both of these trials are currently being produced and evaluated by the company's scientific advisors according to a pre-specified data review procedure. 

Read More
Dipexium gets SME designation in Europe

Dipexium Pharmaceuticals (NASDAQ:DPRX) has been granted small and medium enterprise (SME) designation by the European Medicines Agency (EMA). 

The company recently completed its pivotal Phase 3 clinical trials - OneStep-1 and OneStep-2 - with its topical antimicrobial peptide, Locilex, in mild infections of diabetic foot ulcers in the U.S. under a special protocol assessment agreement from FDA. 

Read More
Dipexium receives Locilex patent in EU

Dipexium Pharmaceuticals (NASDAQ:DPRX) said that the European Patent Office has issued a new Locilex patent in the EU.

The patent claims are directed to a novel formulation of Locilex, a topical antimicrobial peptide formulated as a topical cream, and the use of Locilex as a method of treating skin or wound infections. The issued patent has an expiry date in June 2033.

Read More
Dipexium completes enrollment in one Locilex Phase 3 trial

Dipexium Pharmaceuticals (NASDAQ:DPRX) has completed the patient enrollment objective in the OneStep-2 Phase 3 clinical trial of its Locilex topical antibiotic peptide.

The company’s OneStep-1 Phase 3 clinical trial has passed the 98% enrollment mark and is expected to reach the 180-patient enrollment objective soon.

Read More
Dipexium Pharma receives Locilex patent in Japan

Dipexium Pharmaceuticals (NASDAQ:DPRX) has received a patent in Japan, covering a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry date in June 2033.

“We are delighted to receive a Locilex patent in Japan, the third largest pharmaceuticals market in the world,” David Luci, president and CEO, said in a statement.

Read More
Dipexium Pharma gets Locilex patents in Australia and NZ

Dipexium Pharmaceuticals (NASDAQ:DPRX) said that Australia and New Zealand have issued new Locilex patents, with expiry dates in June 2033.

The patents’ claims are directed to a novel formulation of Locilex, an antibiotic peptide formulated as a topical cream, and use of Locilex as a method of treating skin or wound infections.

Read More